TRNS Stock Analysis: Transcat | NASDAQ
Specialty Business Services | NASDAQ, USA | Market Cap: 826m USD | 12M Return: 6.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.9M
EPS Trend: 5.7%
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Transcat, Inc. (NASDAQ: TRNS) is a provider of calibration and laboratory instrument services operating in the United States, Canada, and internationally. Founded in 1964 and headquartered in Rochester, New York, the company is classified within the Industrials sector under the Trading Companies & Distributors sub-industry, and trades as a small-cap stock with a market capitalization of approximately $861 million. The company has been publicly listed since 1990.
The business operates through two segments: Service and Distribution. The Service segment delivers calibration, repair, inspection, analytical qualification, preventative maintenance, and consulting services. It is supported by CalTrak, a proprietary document and asset management system for calibration workflows, and an online Compliance, Control, and Cost customer portal for managing service records.
The Distribution segment sells and rents test, measurement, and control instruments, complemented by value-added services such as equipment calibration, rental, used equipment sales, and kitting. Marketing channels include the company website, digital and print advertising, outbound sales, and an inbound call center.
Transcat serves highly regulated industries, principally life sciences (pharmaceuticals, biotechnology, medical devices, and other FDA-regulated sectors), along with aerospace and defense, industrial manufacturing, energy and utilities, oil and gas, and chemical manufacturing, all of which require traceable measurement accuracy for compliance and process control.
- Service segment organic growth drives margin expansion
- Life sciences demand from FDA-regulated pharma customers accelerates
- Acquisitions of regional calibration labs expand service network
| Net Income: 6.58m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.63 > 1.0 |
| NWC/Revenue: 15.89% < 20% (prev 15.73%; Δ 0.15% < -1%) |
| CFO/TA 0.07 > 3% & CFO 34.8m > Net Income 6.58m |
| Net Debt (157.3m) to EBITDA (40.6m): 3.88 < 3 |
| Current Ratio: 2.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (9.35m) vs 12m ago 0.98% < -2% |
| Gross Margin: 32.59% > 18% (prev 32.55%; Δ 0.04% > 0.5%) |
| Asset Turnover: 76.83% > 50% (prev 72.55%; Δ 4.28% > 0%) |
| Interest Coverage Ratio: 3.04 > 6 (EBIT TTM 14.4m / Interest Expense TTM 4.74m) |
| A: 0.11 (Total Current Assets 92.5m - Total Current Liabilities 39.6m) / Total Assets 480.5m |
| B: 0.20 (Retained Earnings 97.8m / Total Assets 480.5m) |
| C: 0.03 (EBIT TTM 14.4m / Avg Total Assets 432.9m) |
| D: 1.67 (Book Value of Equity 300.6m / Total Liabilities 179.9m) |
| Altman-Z'' = 3.36 = A |
| DSRI: 0.98 (Receivables 65.8m/56.3m, Revenue 332.6m/279.5m) |
| GMI: 1.00 (GM 32.55% / 32.59%) |
| AQI: 1.14 (AQ_t 0.69 / AQ_t-1 0.60) |
| SGI: 1.19 (Revenue 332.6m / 279.5m) |
| TATA: -0.06 (NI 6.58m - CFO 34.8m) / TA 480.5m) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 92.32 with a total of 90,413 shares traded. Over the past week, the price has changed by +0.65%, over one month by +0.79%, over three months by +10.80% and over the past year by +6.79%.
Current recommended Stop Loss: 87.40 (which is 5.3% or 1.2 ATR below the current price).
Transcat has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold TRNS.
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 101.3 | 9.8% |
P/E Trailing = 155.1053
P/E Forward = 57.1429
P/S = 2.4883
P/B = 2.747
Revenue TTM = 332.6m USD
EBIT TTM = 14.4m USD
EBITDA TTM = 40.6m USD
Long Term Debt = 99.9m USD (from longTermDebt, last quarter)
Short Term Debt = 4.88m USD (from shortTermDebt, two quarters ago)
Debt = 162.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 33.4m
Net Debt = 157.3m USD (calculated: Debt 162.3m - CCE 4.94m)
Enterprise Value = 983.1m USD (825.8m + Debt 162.3m - CCE 4.94m)
Interest Coverage Ratio = 3.04 (Ebit TTM 14.4m / Interest Expense TTM 4.74m)
EV/FCF = 50.35x (Enterprise Value 983.1m / FCF TTM 19.5m)
FCF Yield = 1.99% (FCF TTM 19.5m / Enterprise Value 983.1m)
FCF Margin = 5.87% (FCF TTM 19.5m / Revenue TTM 332.6m)
Net Margin = 1.98% (Net Income TTM 6.58m / Revenue TTM 332.6m)
Gross Margin = 32.59% ((Revenue TTM 332.6m - Cost of Revenue TTM 224.2m) / Revenue TTM)
Gross Margin QoQ = 34.11% (prev 30.11%)
Tobins Q-Ratio = 2.05 (Enterprise Value 983.1m / Total Assets 480.5m)
Interest Expense / Debt = 2.92% (Interest Expense 4.74m / Debt 162.3m)
Taxrate = 32.04% (3.10m / 9.68m)
NOPAT = 9.80m (EBIT 14.4m * (1 - 32.04%))
Current Ratio = 2.33 (Total Current Assets 92.5m / Total Current Liabilities 39.6m)
Debt / Equity = 0.54 (Debt 162.3m / totalStockholderEquity, last quarter 300.6m)
Debt / EBITDA = 3.88 (Net Debt 157.3m / EBITDA 40.6m)
Debt / FCF = 8.06 (Net Debt 157.3m / FCF TTM 19.5m)
Total Stockholder Equity = 296.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.52% (Net Income 6.58m / Total Assets 480.5m)
RoE = 2.22% (Net Income TTM 6.58m / Total Stockholder Equity 296.3m)
RoCE = 3.64% (EBIT 14.4m / Capital Employed (Equity 296.3m + L.T.Debt 99.9m))
RoIC = 2.25% (NOPAT 9.80m / Invested Capital 435.9m)
WACC = 6.76% (E(825.8m)/V(988.1m) * Re(7.70%) + D(162.3m)/V(988.1m) * Rd(2.92%) * (1-Tc(0.32)))
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.41 | Cagr: 2.96%
[DCF] Terminal Value 73.10% ; FCFF base≈22.0m ; Y1≈19.3m ; Y5≈15.6m
[DCF] Fair Price = 9.98 (EV 250.6m - Net Debt 157.3m = Equity 93.2m / Shares 9.34m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 5.70 | EPS CAGR: 0.85% | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.63 | Revenue CAGR: 12.34% | SUE: -0.15 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.38 | Chg30d=-22.44% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.42 | Chg30d=-21.71% | Revisions=-50% | Analysts=4
EPS current Year (2027-03-31): EPS=1.76 | Chg30d=-14.77% | Revisions=-50% | GrowthEPS=-4.3% | GrowthRev=+9.1%
EPS next Year (2028-03-31): EPS=2.14 | Chg30d=-0.35% | Revisions=+25% | GrowthEPS=+21.7% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: -62% (up=1, down=9)